Denosumab is a monoclonal antibody that inhibits bone resorption and is widely used across oncology and osteoporosis-related ...

MADRID, Dec. 22, 2025 /PRNewswire/ -- mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, and Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ: ...

Sandoz has launched Wyost® (denosumab 120 mg) and Jubbonti® (denosumab 60 mg) across Europe, among the first denosumab biosimilars approved for all Xgeva® and Prolia® indications, targeting ...

On November 24, 2025, the U.S. District Court for the District of New Jersey entered a Consent Judgment and Injunction resolving the denosumab BPCIA litigation between Amgen, Inc. and Amgen ...

Temporarily shutting down a "lazy eye" triggers a burst of neuronal activity that reverses the condition in animal experiments, a study shows. When you purchase through links on our site, we may earn ...

∇ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. LONDON, Dec. 2, 2025 /PRNewswire/ -- Accord Healthcare today announced the launch ...

Findings showed denosumab-qbde demonstrated comparable quality, efficacy, safety, and immunogenicity to the reference product. Enoby is approved to treat postmenopausal women with osteoporosis at high ...

In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now. Organon & Co. stands eleventh among them. Organon & Co. (NYSE:OGN), a global healthcare company focused on women ...

Celltrion USA announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo), biosimilars referencing Prolia (denosumab) and Xgeva (denosumab), respectively, are commercially available in the ...

JERSEY CITY, N.J., July 7, 2025 /PRNewswire/ -- Celltrion USA today announced that STOBOCLO ® (denosumab-bmwo) and OSENVELT ® (denosumab-bmwo), biosimilars referencing PROLIA ® (denosumab) and XGEVA ® ...